Brands
pTron India unveils new logo to redefine corporate brand identity
Mumbai: pTron India has unveiled a new brand logo and announced a new bold and futuristic brand identity that will be strengthening the vision of its brand to reach consumers across the value chain of economy, mainstream and premium segments.
The new logo marks the birth of a new pTron both inside and out, which is a modern interpretation of brand’s classic ‘P’ insignia carrying the same passion and zeal to keep making technology accessible to all, said the brand in a statement.
“This new visual identity is in line with the brand’s overall mission, which will be carried out across packaging, branding, and marketing communications. The logo perfectly compliments with the product packaging, providing fresh energy and vibrancy to multiple touch-points,” it added.
These new changes come at a time when the company is also evolving its product offering and services to cater to the youth in major cities of India.
Commenting on the insight behind the new identity, pTron founder and CEO Ameen Khwaja said, “Over the last three years, we did something which is vibrant, connecting, reliable, and of course, gives a sense of being aspirational. Throughout the journey, we have remained true to our core values, even as we continually transform to keep pace with the changing needs of our end consumers.”
“While our name remains the same, our logo & packing have changed significantly to better represent who we are and better connect with our consumers. With our wide Online and offline presence and an extensive Made in India range, we intend to be the preferred choice of the Indian youth looking for tech-savvy gadgets across income-classes. Our belief #BeLoudBeProud lends new meaning to our core purpose of accelerating access to affordable and innovative products,” he added.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
